Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of JMT108 Injection in Participants With Advanced Malignant Tumors

NCT07317505 is registered in ClinicalTrials.gov with Conjupro Biotherapeutics, Inc. as lead sponsor.

NCT NCT07317505
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07317505 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of JMT108 Injection in Participants With Advanced Malignant Tumors
Lead sponsor
Conjupro Biotherapeutics, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
December 2, 2025
Completion date
September 30, 2029
Enrollment
270 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, cancer (solid tumors)